[1] Brown-Elliott BA, Brown JM, Conville PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy[J]. Clin Microbiol Rev, 2006,19(2):259-282. DOI: 10.1128/CMR.19.2.259-282.2006.
[2] Wei M, Xu X, Yang J, et al. MLSA phylogeny and antimicrobial susceptibility of clinical Nocardia isolates: a multicenter retrospective study in China[J]. BMC Microbiol, 2021,21(1):342. DOI: 10.1186/s12866-021-02412-x.
[3] Kageyama A, Poonwan N, Yazawa K, et al. Nocardia asiatica sp. nov., isolated from patients with nocardiosis in Japan and clinical specimens from Thailand[J]. Int J Syst Evol Microbiol, 2004,54 Pt 1:125-130. DOI: 10.1099/ijs.0.02676-0.
[4] Steinbrink J, Leavens J, Kauffman CA, et al. Manifestations and outcomes of nocardia infections: comparison of immunocompromised and nonimmunocompromised adult patients[J]. Medicine (Baltimore), 2018,97(40):e12436. DOI: 10.1097/MD.0000000000012436.
[5] 张盛斌,朱红军,林茂煌,等.肺诺卡菌病12例临床分析[J].中国感染与化疗杂志,2020,20(4):401-405.DOI:10.16718/j.1009-7708.2020.04.011.
[6] 戴望春,曾庆思,周嘉璇,等.肺诺卡菌病胸部CT特征[J].中国医学影像技术,2015,31(7):1049-1052.DOI:10.13929/j.1003-3289.2015.07.023.
[7] Kanne JP, Yandow DR, Mohammed TL, et al. CT findings of pulmonary nocardiosis[J]. AJR Am J Roentgenol, 2011,197(2):W266-272. DOI: 10.2214/AJR.10.6208.
[8] 黄磊.诺卡菌分子鉴定方法的研究进展[J].检验医学与临床,2018,15(18):2814-2817.DOI:10.3969/j.issn.1672-9455.2018.18.040.
[9] Brown-Elliott BA, Biehle J, Conville PS, et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey[J]. J Clin Microbiol, 2012,50(3):670-672. DOI: 10.1128/JCM.06243-11.
[10] Anagnostou T, Arvanitis M, Kourkoumpetis TK, et al. Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature[J]. Medicine (Baltimore), 2014,93(1):19-32. DOI: 10.1097/MD.0000000000000012.
[11] Hamdi AM, Fida M, Deml SM, et al. Retrospective analysis of antimicrobial susceptibility profiles of nocardia species from a tertiary hospital and reference laboratory, 2011 to 2017[J]. Antimicrob Agents Chemother, 2020,64(3):e01868-19. DOI: 10.1128/AAC.01868-19.
[12] Hashemi-Shahraki A, Heidarieh P, Bostanabad SZ, et al. Genetic diversity and antimicrobial susceptibility of Nocardia species among patients with nocardiosis[J]. Sci Rep, 2015,5:17862. DOI: 10.1038/srep17862.
[13] Wang HK, Sheng WH, Hung CC, et al. Clinical characteristics, microbiology, and outcomes for patients with lung and disseminated nocardiosis in a tertiary hospital[J]. J Formos Med Assoc, 2015,114(8):742-749. DOI: 10.1016/j.jfma.2013.07.017.
[14] Brown-Elliott BA, Ward SC, Crist CJ, et al. In vitro activities of linezolid against multiple Nocardia species[J]. Antimicrob Agents Chemother, 2001,45(4):1295-1297. DOI: 10.1128/AAC.45.4.1295-1297.2001.
[15] Srivastava S, Kanaujia R, Sahoo SK, et al. Isolated cerebellar abscess by Norcardia asiatica: a case report with review of literature[J]. J Family Med Prim Care, 2020,9(2):1232-1235. DOI: 10.4103/jfmpc.jfmpc_1005_19.
[16] Okawa S, Sonobe K, Nakamura Y, et al. Pulmonary Nocardiosis due to Nocardia asiatica in an immunocompetent host[J]. J Nippon Med Sch, 2015,82(3):159-162. DOI: 10.1272/jnms.82.159.
[17] 李国玉,高世华,池细俤.肺癌患者术后亚洲诺卡菌肺部感染1例[J].中国感染与化疗杂志,2020,20(4):435-436.DOI:10.16718/j.1009-7708.2020.04.018.
|